3 min read

What ICH-GCP training taught me about documentation in clinical research

In 2024 I completed Good Clinical Practice (GCP) training based on the ICH guidelines for investigators and study teams. The most important lesson was not a specific rule. It was a mindset: in a clinical trial, the documentation is the evidence.
What ICH-GCP training taught me about documentation in clinical research

In 2024 I completed Good Clinical Practice (GCP) training based on the ICH guidelines for investigators and study teams. The most important lesson was not a specific rule. It was a mindset: in a clinical trial, the documentation is the evidence.

A trial can be well designed and carefully run, but if the records cannot show what happened to each participant, regulators cannot rely on the results. This article explains the core documentation principles of GCP and why they matter.

GCP in one paragraph

Good Clinical Practice is an international ethical and scientific quality standard for designing, conducting, recording and reporting clinical trials (International Council for Harmonisation [ICH], 2025). It has two goals: protecting the rights, safety and well-being of participants, and ensuring the reliability of trial results.

The guideline was substantially revised as ICH E6(R3), finalised in January 2025. The revision places more emphasis on quality by design, risk-based approaches and proportionality, while keeping the core principles unchanged (ICH, 2025).

Source data: the starting point of everything

Source data are the original records of clinical findings and observations: medical notes, laboratory reports, pharmacy dispensing records, signed consent forms and patient diaries.

Data entered into the case report form must be traceable back to source. During monitoring, the sponsor checks this through source data verification. If a value in the database cannot be found in the source, it is a finding (ICH, 2025).

This is the ALCOA+ principle applied to clinical research: records must be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring and available.

Key documents at the investigator site

An investigator site maintains a set of essential records, usually in the investigator site file (ICH, 2025). Important examples include:

  • Informed consent forms, signed and dated by the participant and the person obtaining consent, using the approved version.
  • The delegation log, showing which team member is authorised to perform which trial tasks.
  • Training records, demonstrating that each person is qualified for their delegated tasks.
  • Investigational product records, documenting receipt, storage, dispensing, return and destruction.
  • Safety reports, including serious adverse event reports and their submission dates.
  • Protocol deviation records, documenting where the trial did not follow the protocol.

Safety documentation in trials

Safety reporting is where documentation and timing come together. Investigators must report serious adverse events to the sponsor promptly, typically within 24 hours of becoming aware of them (ICH, 2025).

The sponsor then assesses each case. Suspected unexpected serious adverse reactions (SUSARs) are reported to regulators and ethics committees on expedited timelines (ICH, 1994). In Switzerland, these obligations are set out in the Clinical Trials Ordinance (KlinV), and trials must be approved by the competent ethics committee and, for medicinal product trials, by Swissmedic (Clinical Trials Ordinance [KlinV], 2013; Human Research Act [HRA], 2011).

The quality of the initial site report determines how well the sponsor can assess the case. The same four elements I look for in a pharmacy ADR report apply here: an identifiable patient, a reporter, a suspect product and an event, plus clear dates.

Investigational product: where pharmacy meets GCP

Pharmacists often play a central role in managing investigational products. Accountability means that every unit can be traced from delivery to its final use or destruction (ICH, 2025).

That requires controlled storage with temperature monitoring, accurate dispensing logs, blinding protection where relevant, and reconciliation of returned products. These are familiar tasks from hospital pharmacy, where I managed peri-surgical medication supply and maintained rigorous records in a multi-team environment.

Common documentation findings

Audit and inspection findings at sites often involve the same issues:

  • consent obtained with an outdated form version;
  • tasks performed by staff not listed on the delegation log;
  • missing or late serious adverse event reports;
  • discrepancies between source documents and case report forms;
  • incomplete investigational product accountability.

Most are preventable with clear procedures, regular self-checks and a team culture that treats documentation as part of patient care.

Why GCP knowledge matters beyond clinical operations

GCP principles also matter in pharmacovigilance, regulatory affairs and quality assurance. Safety teams process trial cases and prepare development safety update reports (ICH, 2010). Regulatory teams submit trial data in marketing applications. Quality teams audit sites and vendors.

Understanding how site documentation works helps each of these functions ask the right questions.

Why this matters to employers

Companies running clinical trials need people who understand GCP not as a certificate, but as a working method. My GCP training, combined with years of regulated pharmacy documentation and structured research documentation in my thesis, prepares me to contribute to trial-related safety, quality and regulatory work.

Key takeaways

  • In clinical trials, documentation is the evidence that a trial was conducted properly.
  • Source data must support every value in the trial database.
  • Safety reporting depends on prompt, complete site documentation.

References

Clinical Trials Ordinance [KlinV] of 20 September 2013, SR 810.305 (Switzerland). https://www.fedlex.admin.ch

Human Research Act [HRA] of 30 September 2011, SR 810.30 (Switzerland). https://www.fedlex.admin.ch

International Council for Harmonisation. (1994). Clinical safety data management: Definitions and standards for expedited reporting E2A. https://www.ich.org

International Council for Harmonisation. (2010). Development safety update report E2F. https://www.ich.org

International Council for Harmonisation. (2025). Guideline for good clinical practice E6(R3). https://www.ich.org